Amantakul Amonlaya, Amantakul Akara, Pojchamarnwiputh Suwalee, Chattipakorn Nipon, Chattipakorn Siriporn Chaisin, Sripetchwandee Jirapas
Department of Diagnostic Radiology, Faculty of Medicine, Chiang Mai University, Chiang Mai, Thailand.
Department of Urology, Faculty of Medicine, Chiang Mai University, Chiang Mai, Thailand.
Clin Transl Oncol. 2024 Dec 16. doi: 10.1007/s12094-024-03784-y.
Prostate cancer is one of the major causes of morbidity and mortality in men worldwide. Most patients with prostate cancer will turn into end-of-life stage when those tumor cells become metastatic castration-resistant prostate cancer (mCRPC). The mCRPC subsequently developed a resistance to androgen signaling. The current regimens for mCRPC therapy are still ineffective. Much evidence from in vitro and in vivo studies explored the roles of therapeutic interventions targeted at the mitochondria and programmed cell death for prostate cancer therapy. The present review will focus on the recent medications which targeted at mitochondria and programmed cell death in mCRPC and the significant findings from each study will be summarized and discussed. Development of therapeutic interventions, particularly at mitochondrial and cytotoxic targets for treatment of mCRPC without inducing cellular toxicity of normal tissues will be considered as the novel therapeutic strategy for mCRPC.
前列腺癌是全球男性发病和死亡的主要原因之一。大多数前列腺癌患者在肿瘤细胞发展为转移性去势抵抗性前列腺癌（mCRPC）时，将进入生命末期。mCRPC随后对雄激素信号产生耐药性。目前用于mCRPC治疗的方案仍然无效。来自体外和体内研究的大量证据探讨了针对线粒体和程序性细胞死亡的治疗干预措施在前列腺癌治疗中的作用。本综述将聚焦于近期针对mCRPC中线粒体和程序性细胞死亡的药物，并对每项研究的重要发现进行总结和讨论。开发治疗干预措施，特别是针对线粒体和细胞毒性靶点来治疗mCRPC而不诱导正常组织的细胞毒性，将被视为mCRPC的新型治疗策略。
